October 19, 2021

In a Single Real-World Deployment of over 1,300 Patients, Spire Health’s RPM Service Escalated Patients experiencing Respiratory Exacerbation with 68% Accuracy

Spire Health, the leading provider of remote patient monitoring (RPM) for chronic respiratory disease patients, today announced the results of a real-world study of 1,366 patients at a Virginia-based, multi-provider pulmonary clinic. Among the 188 escalations using Spire’s AI-based system, 68% were pharmacologically treated for acute exacerbation by their pulmonologist. The primary investigator and lead author, Dr. Michael Polsky, presented the results during the CHEST Annual Meeting 2021, held virtually October 17-20, 2021.

“These findings demonstrate preliminary evidence of the clinical impact of respiration-focused remote monitoring combined with processes for triaging our pulmonary patients,” said Dr. Michael Polsky, Pulmonary Associates of Richmond. “The RPM system identifies baseline deviations in respiration, pulse rate, and activity then triggers a notification to respiratory therapists (RTs). These patients are contacted within 48 hours by the therapist and, if needed, escalated to be seen by their doctor. In over 68% of instances, this process led to pharmacologic intervention consistent with a definition of an acute exacerbation. This combination of automated and human assessment helped us catch changes in patient condition and treat those early symptoms in an effort to avoid further patient deterioration and potential hospitalization.”

In the abstract, Anticipating acute deterioration in respiratory disease using remote monitoring of respiratory force, researchers retrospectively analyzed the chart data of 164 pulmonary patients enrolled on Spire RPM who were escalated to their provider at the Pulmonary Associates of Richmond (Richmond, VA). The 68.6% of the escalations that were found to require intervention were further broken down by intervention:

●     33.0% were changes in steroids and/or antibiotics

●     20.2% inhaled respiratory medication

●     15.4% both (changes in steroids/antibiotics and inhaled respiratory medication)

●     31.4% no pharmacological intervention

“Early identification and management of exacerbations in chronic respiratory conditions, such as COPD, is important to prevent acute deterioration which leads to emergency room visits and hospitalization,” said Neema Moraveji, Ph.D., co-author and Chief Science Officer of Spire Health. “We are thrilled to provide preliminary evidence that a respiration-focused RPM system can identify at-risk patients and ensure they are treated sooner. This is a key step towards Spire’s goal of driving down long-term hospitalization rate in chronic respiratory disease patients and improving patient outcomes.”

To learn how Spire RPM can benefit your practice

Contact Us